Saturday 17 October 2026
Export KPRX’s income statement to Excel — free account
Kiora Pharmaceuticals, Inc.
KPRX Healthcare Biotechnology
Kiora Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $16.0 million. In the quarter to June 2026, EPS grew 37.0% and free cash flow grew 50.1%, each against the same quarter a year earlier.
2.40
0.01
−0.41%
Follow KPRX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (56.36%) | (58.78%) | (51.74%) | (32.58%) |
+8 more TTM periods Free account |
|
| (39.43%) | (40.04%) | (35.68%) | (24.99%) | ||
ROIC |
(44,053.91%) | (13,010.90%) | 0.00% | (166.49%) | |
Return on Tangible Assets |
(57.85%) | (69.25%) | (59.51%) | (42.26%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.39) | (2.52) | (2.41) | (2.37) | |
Free Cash Flow |
(8.61) | (10.53) | (10.03) | (10.02) | |
Capital Expenditures |
(0.11) | (0.12) | (0.07) | 0.01 | |
| Other line items | |||||
Cash ROIC |
(25.56%) | (37.88%) | (30.19%) | (23.98%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | (0.11) | (0.09) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.77 | 0.94 | 0.92 | 1.17 | |
Depreciation/Fixed assets |
0.43 | 0.40 | 0.27 | 0.20 | |
Capex/Depreciation |
(2.53) | (3.30) | (2.65) | 0.61 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.38) | (2.50) | (2.39) | (2.37) | |
Capex per Share |
(0.02) | (0.03) | (0.02) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates